ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0729

ANCA-associated vasculitis – does the type matter?

Tamanna Vinodkumar Mohta1 and Umeh Chukwuemeka2, 1Hemet Global Medical Center, Irvine, CA, 2Hemet Global Medical Center, Hemet

Meeting: ACR Convergence 2025

Keywords: ANCA associated vasculitis, Cardiovascular, interstitial lung disease, Myocardial Infarction, Wegener's

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0711–0730) Vasculitis – ANCA-Associated Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis is a heterogeneous group of rare autoimmune disorders that cause inflammation of blood vessels with various manifestations. Our study compares the differences in clinical outcomes in patients with the three main ANCA–associated vasculitis, granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA).

Methods: We analyzed data of patients hospitalized with a primary or secondary diagnosis of ANCA-vasculitis admitted in United States hospitals from 2017 to 2021 using the National Inpatient Sample (NIS) data. The NIS database is the largest publicly available database of patients hospitalized in the United States.

Results: There were 77,100 patients with a diagnosis of ANCA-associated vasculitis with a mean age of 61.3 years. Of this, 56965 (73.9%) had GPA, 11020 (14.3%) MPA, and 9115 (11.8%) EGPA. In the bivariate analysis, MPA patients had more kidney, heart, and lung complications and worse outcomes compared to GPA and EGPA patients. MPA patients when compared to GPA and EGPA patients were more likely to have acute kidney injury (47.9% vs. 30.2% vs. 21.2%), end-stage renal disease (31.2% vs. 24.2% vs. 3.5%), acute myocardial infarction (5.1% vs. 4.1% vs. 4.1%), congestive heart failure (31.3% vs. 24.9% vs. 23.3%), pulmonary hypertension (9.7% vs. 6.5% vs. 5.3%) and interstitial lung disease (11.9% vs. 4.6% vs. 4.5%), all with p< 0.001. There was no difference in the prevalence of ischemic stroke between the MPA, GPA, and EGPA (p=0.88). In the multivariate analysis with GPA as the reference group, there was no difference in in-hospital all-cause mortality between GPA and MPA patients (aOR 0.98, 95% CI 0.89-1.08). However, EGPA patients had lower mortality than GPA patients (aOR 0.67, 95% CI 0.58-0.77).

Conclusion: GPA is the most common type of ANCA vasculitis in hospitalized patients in the US. Kidney involvement, interstitial lung disease, and acute myocardial infarction appear to be more common in MPA than other ANCA vasculitis. However, MPA patients did not have worse in-patient all-cause mortality than GPA patients. EGPA patients appear to have the best in-hospital prognosis.

Supporting image 1Table 1: Comparing various demographics and complications in different types of ANCA-associated vasculitis.


Disclosures: T. Mohta: None; U. Chukwuemeka: None.

To cite this abstract in AMA style:

Mohta T, Chukwuemeka U. ANCA-associated vasculitis – does the type matter? [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/anca-associated-vasculitis-does-the-type-matter/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anca-associated-vasculitis-does-the-type-matter/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology